Patricia Snarski1,2, Sergiy Sukhanov1,2, Tadashi Yoshida1,2, Yusuke Higashi1,2, Svitlana Danchuk1,2, Bysani Chandrasekar3,4, Di Tian5, Vikara Rivera-Lopez6, Patrick Delafontaine1,2,7. 1. Section of Cardiology, John W. Deming Department of Medicine (P.S., S.S., T.Y., Y.H., S.D., P.D.), Tulane University School of Medicine, New Orleans, LA. 2. Department of Physiology (P.S., S.S., T.Y., Y.H., S.D., P.D.), Tulane University School of Medicine, New Orleans, LA. 3. Research Service, Harry S. Truman Memorial Veterans' Hospital, Columbia, MO (B.C.). 4. Department of Medical Pharmacology and Physiology, University of Missouri, Columbia (B.C.). 5. Department of Pathology (D.T.), Tulane University School of Medicine, New Orleans, LA. 6. Loyola University, New Orleans, LA (V.R.-L.). 7. Department of Pharmacology (P.D.), Tulane University School of Medicine, New Orleans, LA.
Abstract
OBJECTIVE: IGF-1 (insulin-like growth factor 1) exerts pleiotropic effects including promotion of cellular growth, differentiation, survival, and anabolism. We have shown that systemic IGF-1 administration reduced atherosclerosis in Apoe-/- (apolipoprotein E deficient) mice, and this effect was associated with a reduction in lesional macrophages and a decreased number of foam cells in the plaque. Almost all cell types secrete IGF-1, but the effect of macrophage-derived IGF-1 on the pathogenesis of atherosclerosis is poorly understood. We hypothesized that macrophage-derived IGF-1 will reduce atherosclerosis. Approach and Results: We created macrophage-specific IGF-1 overexpressing mice on an Apoe-/- background. Macrophage-specific IGF-1 overexpression reduced plaque macrophages, foam cells, and atherosclerotic burden and promoted features of stable atherosclerotic plaque. Macrophage-specific IGF1 mice had a reduction in monocyte infiltration into plaque, decreased expression of CXCL12 (CXC chemokine ligand 12), and upregulation of ABCA1 (ATP-binding cassette transporter 1), a cholesterol efflux regulator, in atherosclerotic plaque and in peritoneal macrophages. IGF-1 prevented oxidized lipid-induced CXCL12 upregulation and foam cell formation in cultured THP-1 macrophages and increased lipid efflux. We also found an increase in cholesterol efflux in macrophage-specific IGF1-derived peritoneal macrophages. CONCLUSIONS: Macrophage IGF-1 overexpression reduced atherosclerotic burden and increased features of plaque stability, likely via a reduction in CXCL12-mediated monocyte recruitment and an increase in ABCA1-dependent macrophage lipid efflux.
OBJECTIVE: IGF-1 (insulin-like growth factor 1) exerts pleiotropic effects including promotion of cellular growth, differentiation, survival, and anabolism. We have shown that systemic IGF-1 administration reduced atherosclerosis in Apoe-/- (apolipoprotein E deficient) mice, and this effect was associated with a reduction in lesional macrophages and a decreased number of foam cells in the plaque. Almost all cell types secrete IGF-1, but the effect of macrophage-derived IGF-1 on the pathogenesis of atherosclerosis is poorly understood. We hypothesized that macrophage-derived IGF-1 will reduce atherosclerosis. Approach and Results: We created macrophage-specific IGF-1 overexpressing mice on an Apoe-/- background. Macrophage-specific IGF-1 overexpression reduced plaque macrophages, foam cells, and atherosclerotic burden and promoted features of stable atherosclerotic plaque. Macrophage-specific IGF1 mice had a reduction in monocyte infiltration into plaque, decreased expression of CXCL12 (CXC chemokine ligand 12), and upregulation of ABCA1 (ATP-binding cassette transporter 1), a cholesterol efflux regulator, in atherosclerotic plaque and in peritoneal macrophages. IGF-1 prevented oxidized lipid-induced CXCL12 upregulation and foam cell formation in cultured THP-1 macrophages and increased lipid efflux. We also found an increase in cholesterol efflux in macrophage-specific IGF1-derived peritoneal macrophages. CONCLUSIONS: Macrophage IGF-1 overexpression reduced atherosclerotic burden and increased features of plaque stability, likely via a reduction in CXCL12-mediated monocyte recruitment and an increase in ABCA1-dependent macrophage lipid efflux.
Entities:
Keywords:
atherosclerosis; cytokines; inflammation; intercellular signaling peptides and proteins; lipids
Authors: Timo Heidt; Gabriel Courties; Partha Dutta; Hendrik B Sager; Matt Sebas; Yoshiko Iwamoto; Yuan Sun; Nicolas Da Silva; Peter Panizzi; Anja M van der Laan; Anja M van der Lahn; Filip K Swirski; Ralph Weissleder; Matthias Nahrendorf Journal: Circ Res Date: 2014-05-01 Impact factor: 17.367
Authors: Salim S Virani; Alvaro Alonso; Emelia J Benjamin; Marcio S Bittencourt; Clifton W Callaway; April P Carson; Alanna M Chamberlain; Alexander R Chang; Susan Cheng; Francesca N Delling; Luc Djousse; Mitchell S V Elkind; Jane F Ferguson; Myriam Fornage; Sadiya S Khan; Brett M Kissela; Kristen L Knutson; Tak W Kwan; Daniel T Lackland; Tené T Lewis; Judith H Lichtman; Chris T Longenecker; Matthew Shane Loop; Pamela L Lutsey; Seth S Martin; Kunihiro Matsushita; Andrew E Moran; Michael E Mussolino; Amanda Marma Perak; Wayne D Rosamond; Gregory A Roth; Uchechukwu K A Sampson; Gary M Satou; Emily B Schroeder; Svati H Shah; Christina M Shay; Nicole L Spartano; Andrew Stokes; David L Tirschwell; Lisa B VanWagner; Connie W Tsao Journal: Circulation Date: 2020-01-29 Impact factor: 29.690
Authors: A Musarò; K McCullagh; A Paul; L Houghton; G Dobrowolny; M Molinaro; E R Barton; H L Sweeney; N Rosenthal Journal: Nat Genet Date: 2001-02 Impact factor: 38.330
Authors: Elias Stratikopoulos; Matthias Szabolcs; Ioannis Dragatsis; Apostolos Klinakis; Argiris Efstratiadis Journal: Proc Natl Acad Sci U S A Date: 2008-11-25 Impact factor: 11.205
Authors: Michelle C Flynn; Gerard Pernes; Man Kit Sam Lee; Prabhakara R Nagareddy; Andrew J Murphy Journal: Front Pharmacol Date: 2019-06-13 Impact factor: 5.810